Literature DB >> 9143467

Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer.

S Ho1, W Y Lau, T W Leung, M Chan, P J Johnson, A K Li.   

Abstract

Radiation doses to the tumour and non-tumorous liver compartments from yttrium-90 microspheres in the treatment of hepatic cancer, as estimated by a partition model, have been verified by correlation with the actual doses measured with a beta probe at open surgery. The validity of the doses to the lungs, the tumour and non-tumorous liver compartment as estimated by the partition model was further evaluated in clinical settings. On the basis of the observation that one of three patients who received more than 30 Gy from a single treatment and one of two patients who received more than 50 Gy from multiple treatments developed radiation pneumonitis, it was deduced that an estimated lung dose < 30 Gy from a single treatment and a cumulative lung dose < 50 Gy from multiple treatments were probably the tolerance limits of the lungs. Three of five patients who received lung doses > 30 Gy as estimated by the partition model and were predicted to develop radiation pneumonitis, did so despite the use of partial hepatic embolization to reduce the degree of lung shunting. Furthermore, a higher radiological response rate and prolonged survival were found in the group of patients who received higher tumour doses, as estimated by the partition model, than in the group with lower estimated tumour doses. Thus the radiation doses estimated by the partition model can be used to predict (a) complication rate, (b) response rate and (c) duration of survival in the same manner as the actual radiation doses measured with a beta probe at open surgery. The partition model has made selective internal radiation therapy using 90Y microspheres safe and repeatable without laparotomy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143467     DOI: 10.1007/bf01728766

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  49 in total

1.  Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Authors:  Wolfgang Peter Fendler; Harun Ilhan; Philipp M Paprottka; Tobias F Jakobs; Volker Heinemann; Peter Bartenstein; Feras Khalaf; Samer Ezziddin; Marcus Hacker; Alexander R Haug
Journal:  Eur Radiol       Date:  2015-02-28       Impact factor: 5.315

2.  Non-surgical treatment of hepatocellular carcinoma.

Authors:  Philip J Johnson
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

Review 4.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

5.  Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.

Authors:  Chi Lai Ho; Sirong Chen; Shing Kee Cheung; Yim Lung Leung; Kam Chau Cheng; Ka Nin Wong; Yuet Hung Wong; Thomas Wai Tong Leung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-11       Impact factor: 9.236

Review 6.  Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases.

Authors:  Abdul Saied; Steven C Katz; N Joseph Espat
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

7.  (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.

Authors:  Mattijs Elschot; Johannes F W Nijsen; Marnix G E H Lam; Maarten L J Smits; Jip F Prince; Max A Viergever; Maurice A A J van den Bosch; Bernard A Zonnenberg; Hugo W A M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-13       Impact factor: 9.236

8.  99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres.

Authors:  Bieke Lambert; Jeroen Mertens; Emiel J Sturm; Steven Stienaers; Luc Defreyne; Yves D'Asseler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-04       Impact factor: 9.236

9.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.

Authors:  Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2006-12-06       Impact factor: 5.315

Review 10.  Challenge and hope in radiotherapy of hepatocellular carcinoma.

Authors:  Jinsil Seong
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.